Our experiments show a strong reduction of resurgent currents by this compound, suggesting that using drugs that selectively target SI of Nav1.7 may be helpful in the future to treat patients suffering from PEPD or other forms of pain. The gene discussed is SCN9A; the disease is paroxysmal extreme pain disorder.